Aug 2026· Expert opinion on therapeutic targets· 0 citations· 93 references
Medicine
TL;DR
PfPDI inhibitors are most likely to succeed as components of resistance-robust combination therapies, and progress will depend on structure-guided targeting of divergent non-catalytic surfaces, optimization of intracellular and ER exposure, and rigorous in-parasite target-engagement studies.
Abstract
INTRODUCTION
The emergence of partial resistance to artemisinin-based therapies has intensified the search for antimalarial targets beyond classical kinases and proteases. Protein disulfide isomerases (PDIs) have emerged as attractive candidates due to their roles in endoplasmic reticulum (ER) oxidative folding, redox homeostasis, and survival under proteotoxic stress. Several Plasmodium falciparum PDI family members are essential during asexual blood stages and contribute to parasite transmission.
AREAS COVERED
We summarize PfPDI architecture, catalytic and holdase functions, and their integration within the parasite ER folding network, highlighting structural divergence from human PDIs that may enable selective inhibition. We review PDI-directed chemotypes, including covalent active-site binders and non-covalent/allosteric modulators, and highlight the absence of PfPDI-selective probes with validated intracellular mechanisms. We further discuss approaches for target validation, including chemoproteomics, activity-based profiling, and chemical genetics, alongside medicinal chemistry considerations for achieving exposure to an intracellular ER target. Finally, we examine PfPDIs within a proteostasis-stress framework and discuss combination strategies with protein-damaging agents such as artemisinin derivatives.
EXPERT OPINION
Progress will depend on structure-guided targeting of divergent non-catalytic surfaces, optimization of intracellular and ER exposure, and rigorous in-parasite target-engagement studies. PfPDI inhibitors are most likely to succeed as components of resistance-robust combination therapies.
This study sought to identify peptides that mimic the substrates of PfGrp78, which can be potential inhibitors of PfGrp78, and explored the mechanism of action of cyclodecapeptides, gramicidin S (GS) and tyrocidines (Trcs), which were previously shown to exhibit potent antimalarial activity.
Wendy Mthembu, A. Odugbemi, F. L. Muzenda et al.· Journal of Computer-Aided Mo...· 0 citations
This review summarizes recent advances in chemical protein degradation strategies for neurodegenerative disorders and highlights potential future perspectives of multifunctional PROTACs for therapeutic development.
Pasquale Degennaro, Imane Ghafir El Idrissi, Rosa Purgatorio et al.· Pharmaceuticals· 0 citations
A structure‐informed, deconstruction‐based approach is applied to identify non‐peptidomimetic PMV inhibitors by mining catalytic dyad‐binding motifs from experimentally solved aspartic protease–inhibitor complexes and assembling a focused fragment‐like library.
M. Skvorcova, Laura Ruduša, D. Zelencova-Gopejenko et al.· ChemMedChem· 0 citations
Cryo-EM structural studies reveal a novel binding pose of the inhibitor at the Pf 20S β 5 active site, explaining the enhanced activity of an N -cap sulfonamide modification compared to an N -cap amide, and offer insights into the development of next-generation antimalarial Pf 20S-targeting compounds with improved drug...
Hao Zhang, Da-Qiang Li, Hao-Chi Hsu et al.· 0 citations
This review aims to synthesize current biochemical, structural, genetic, and transcriptomic evidence on Plasmodium glutathione S-transferases and evaluate their role in parasite physiology across the life cycle while revising their potential for drug targeting using suggested guidelines for target candidate profiling a...
Maria Luiza Lima, Nele Wild, Eva Liebau et al.· Pharmaceuticals· 0 citations
Current knowledge on Plasmodium HKMTs is synthesized, highlighting their biochemical activities, regulatory roles, and contributions to virulence, while evaluating emerging epigenetic inhibitors as potential antimalarial agents.
Ezhumalai Parthiban, R. Ramanibai, M. Ramachandran· Molecular and biochemical pa...· 0 citations
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.